Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133624 | 0.83 | ALDH1A1 (0.38) | ALDH1A1TSHRGLALMNAHSD11B1 | |
| SCHEMBL19243123 | 0.81 | ALDH1A1 (0.38) | ALDH1A1TSHRGLAHSD11B1MEN1 | |
| SCHEMBL20677745 | 0.77 | GAA (0.45) | ALDH1A1TSHRLMNAHSD11B1HSP90AA1 | |
| SCHEMBL10984998 | 0.75 | ALDH1A1 (0.48) | ALDH1A1TSHRGLALMNAHSD11B1 | |
| SCHEMBL2325563 | 0.75 | LMNA (0.45) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| SCHEMBL14696636 | 0.72 | ALDH1A1 (0.56) | ALDH1A1TSHRGLALMNAHSP90AA1 | |
| SCHEMBL1072478 | 0.70 | ALDH1A1 (0.50) | ALDH1A1TSHRGLALMNAHSD11B1 | |
| SCHEMBL354359 | 0.70 | ALDH1A1 (0.49) | ALDH1A1TSHRGLALMNAHSD11B1 | |
| SCHEMBL1549585 | 0.69 | FFAR3 (0.36) | — | |
| SCHEMBL25568411 | 0.69 | ALDH1A1 (0.52) | ALDH1A1TSHRGLALMNAHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | EMCURE PHARMACEUTICALS LIMITED (IN) | 2019-01-31 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| WO-2016131380-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO.,LTD. (CN) | 2016-08-25 | — | — | WO | disclosed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1904455-A2 | PYRIDAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007003521-A2 | PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-11 | — | — | WO | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
| US-4510323-A | ANTICOAGULANTS; HYPOTENSIVE AGENTS; ANTISECRETARY AGENTS; PROSTAGLANDINS | GRUENENTHAL GMBH (DE) | 1985-04-09 | — | — | US | disclosed |
| EP-0038131-B1 | BICYCLOOCTANE COMPOUNDS, THEIR PRODUCTION, COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-08-08 | — | — | EP | disclosed |
| US-4400393-A | Novel bicyclooctane compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-08-23 | — | — | US | disclosed |
| EP-0038131-A2 | Bicyclooctane compounds, their production, compositions containing them and their pharmaceutical use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | ALDH1A1 2128/4885TSHR 2589/4885GLA 2293/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | ALDH1A1 2128/4885TSHR 2589/4885GLA 2293/4885 |
| US-20190031665-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | IDO1, IDO2, TDO2 | ALDH1A1 946/4885TSHR 2460/4885GLA 2516/4885 |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | ALDH1A1 91/4885TSHR 1422/4885GLA 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.